Search research articles
Contact Us
Filters
Showing results (501-510 of 636) with videos related to
Page
of 64
Sort By:
Circulation
|
November 12, 2019
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial
Christopher P Cannon, Vlado Perkovic, Rajiv Agarwal, et al.
Journal of the American College of Cardiology
|
February 9, 2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
Manesh R Patel, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Stroke
|
April 19, 2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation
Graeme J Hankey, Susanna R Stevens, Jonathan P Piccini, et al.
International Journal of Cardiology
|
June 26, 2018
Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials
Christoph B Olivier, Vandana Sundaram, Deepak L Bhatt, et al.
International Journal of Cardiology
|
February 21, 2012
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years
Mark Y Chan, Jie-Lena Sun, L Kristin Newby, et al.
Journal of the American College of Cardiology
|
October 27, 2022
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria
Ashish Sarraju, George Bakris, Christopher P Cannon, et al.
International Journal of Cardiology
|
February 12, 2013
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy
Sean van Diepen, L Kristin Newby, Renato D Lopes, et al.
Coronary Artery Disease
|
February 28, 2013
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial
Sergio Leonardi, Amanda Stebbins, Renato D Lopes, et al.
Circulation. Cardiovascular Quality and Outcomes
|
June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience
Kenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
Journal of Clinical and Translational Science
|
September 25, 2023
The evolving role of data & safety monitoring boards for real-world clinical trials
Bryan J Bunning, Haley Hedlin, Jonathan H Chen, et al.
Page
of 64
Search research articles
Search
Showing results (501-510 of 636) with videos related to
Sort By:
Page
of 64
Circulation
|
November 12, 2019
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial
Christopher P Cannon, Vlado Perkovic, Rajiv Agarwal, et al.
Journal of the American College of Cardiology
|
February 9, 2013
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
Manesh R Patel, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Stroke
|
April 19, 2014
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation
Graeme J Hankey, Susanna R Stevens, Jonathan P Piccini, et al.
International Journal of Cardiology
|
June 26, 2018
Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials
Christoph B Olivier, Vandana Sundaram, Deepak L Bhatt, et al.
International Journal of Cardiology
|
February 21, 2012
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years
Mark Y Chan, Jie-Lena Sun, L Kristin Newby, et al.
Journal of the American College of Cardiology
|
October 27, 2022
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria
Ashish Sarraju, George Bakris, Christopher P Cannon, et al.
International Journal of Cardiology
|
February 12, 2013
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy
Sean van Diepen, L Kristin Newby, Renato D Lopes, et al.
Coronary Artery Disease
|
February 28, 2013
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial
Sergio Leonardi, Amanda Stebbins, Renato D Lopes, et al.
Circulation. Cardiovascular Quality and Outcomes
|
June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience
Kenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
Journal of Clinical and Translational Science
|
September 25, 2023
The evolving role of data & safety monitoring boards for real-world clinical trials
Bryan J Bunning, Haley Hedlin, Jonathan H Chen, et al.
Page
of 64